Hypertrophic Cardiomyopathy: Comprehensive Management of a Complex Disease is organized by New York University (NYU) School of Medicine and will be held from Apr 27 - 28, 2019 at NYU Langone Health, New York City, New York, United States of America.
The target audience for this medical event is Physicians, physician trainees, advanced practice providers, nurses, physician assistants, and allied health professionals. This CME Conference has been approved for a maximum of 14.75 AMA PRA Category 1 Credits.
Course Description :
Hypertrophic cardiomyopathy (HCM) is one of the most challenging diseases encountered in cardiology practice because of the diversity of its expression and its unpredictable clinical course. In the last two decades HCM care has seen the development of highly effective interventions that prevent sudden death, relieve symptoms, and prevent stroke. Parallel to this evolution has been the movement from office care to in-hospital care for interventions. The lecturers at this course are national and international thought leaders in the realm of HCM care. They will discuss latest electrophysiologic, medical, and surgical advances including: indications and judgement for ICD implantation including when an IV-ICD or S-ICD might be chosen, the crucial role of anticoagulation for AFib, and when AF ablation might be indicated. The safety of outpatient initiation of disopyramide will be discussed, as well as the effect of this agent on isolated HCM cardiomyocytes. Trials of the novel agent mavacamten for obstructive and non-obstructive HCM will be discussed. Video of extended myectomy and novel ancillary surgical approaches to the mitral valve will be demonstrated. Current echocardiographic and MRI diagnosis will be covered, as well as TEE planning and monitoring of myectomy. Practical family counseling, non-invasive screening, and genotype analysis will be covered. Pre-participation screening for students and athletes will be discussed. Automatic defibrillator deployment in schools will be highlighted.
Course Objectives :
After participating in this activity, clinicians should be able to:
• Accurately interpret echocardiographic findings for the appropriate diagnosis of HCM, adequately distinguish and differentiate between major and minor risks for sudden cardiac death in HCM patients, and identify massive thickening on echocardiography or MRI that should prompt consideration of ICD
• Recognize when disopyramide should be started for obstruction, and safely initiate disopyramide to outpatients
• Apply guideline recommendations and manage co-morbidities adequately
• Propose individually tailored recommendations regarding invasive therapy, surgery or ablation for obstructive HCM and adequately explain risks and benefits of each option, and understand how mitral abnormalities skew recommendations towards surgery
• Appropriately offer family counseling, non-invasive screening, and genotype analysis for patients and family members of those with HCM
• Perform thorough pre–athletic screening history and physical and discuss and describe current AED recommendations
Note: After 12 pm on April 24, 2019 only onsite registration is available, provided the course has not reached capacity. Onsite registrants will incur an additional $20 charge.
Additional details will be posted as soon as they are available.
|Contact No. :||212.263.5295
|Registration Type||End Date||Price|
|Full Fee||24 Apr,2019||USD 350.00|
|Reduced Fee||24 Apr,2019||USD 75.00|
|NYU Langone Faculty and Staff Fee||24 Apr,2019||USD 150.00|
|Cardiology and Internal Medicine Residents and Cardiology Fellows Fee||24 Apr,2019||Free|